Memorial Sloan–Kettering Cancer Center (MSKCC) is a cancer treatment and research institution founded in 1884 as the New York Cancer Hospital. The main campus is located at 1275 York Avenue, between 67th and 68th Streets in New York City, with other locations in Basking Ridge, New Jersey, Long Island and Westchester County, New York. MSKCC is actually composed of two intimately related institutions. Memorial Hospital for Cancer and Allied Diseases, currently led by Physician-In-Chief, Dr. Robert Wittes, provides patient care, whose origins stemmed from a medical laboratory established on the campus of Cornell Medical Center and funded by John D. Rockefeller, in 1900. The original Memorial Hospital building was designed by Henry C. Pelton and constructed in 1939 by a group that included John J. Astor and his wife, Charlotte. Between 1970 and 1973 a new memorial hospital was built on the same site—originally donated by John D. Rockefeller, Jr. Sloan–Kettering Institute, currently led by Dr. Thomas Kelly, is MSKCC's basic-science research arm. The research institute was established in 1945 with a US$4 million gift from the foundation of Alfred P. Sloan, Jr.
Some content from Wikipedia, licensed under CC BY-SA
Subscribe to rss feed
A new immunotherapy drug, atezolizumab, has been approved for patients with metastatic urothelial carcinoma, a type of bladder cancer. The drug represents the first new treatment for this form of the disease in more than ...
Jun 1, 2016
0
115
The lack of participation in clinical research may be the Achilles' heel of today's cancer community. According to a new survey of more than 1,500 consumers and nearly 600 physicians conducted on behalf of Memorial Sloan ...
May 24, 2016
1
18
Even after successful treatment, cancer can sometimes come back years later and spread to different organs. This is called latent metastasis. A new study by MSK scientists sheds light on how cancer cells hide out and remain ...
Apr 1, 2016
0
207
Today, the US Food and Drug Administration (FDA) approved the immunotherapy combination nivolumab (Opdivo) plus ipilimumab (Yervoy) for use in patients with metastatic melanoma. This is the first-ever combination immunotherapy ...
Oct 5, 2015
0
15
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations ...
Aug 20, 2015
0
19
A new type of cancer therapy that targets an oncometabolite produced dramatic results in patients with advanced leukemia in an early-phase clinical trial. The study, led by Eytan M. Stein, MD, a medical oncologist at Memorial ...
Dec 7, 2014
0
1
In recent years, a number of scientific breakthroughs have led to the development of drugs that unleash the power of the immune system to recognize and attack cancer. Studies presented today at the 56th Annual Meeting of ...
Dec 6, 2014
0
0
In a late-stage clinical trial, Hodgkin lymphoma (HL) patients who received brentuximab vedotin (BV) post-transplant lived longer without disease progression than patients who received only supportive care. This is the first ...
Dec 6, 2014
0
0
Bacterial infections can cause major problems for people undergoing treatment for cancer and other diseases. The concern is especially acute during hospitalization, when patients often have weakened immune function.
Oct 23, 2014
0
0
Research led by investigators at Memorial Sloan Kettering Cancer Center has shown for the first time that organoids derived from human prostate cancer tumors can be grown in the laboratory, giving researchers an exciting ...
Sep 4, 2014
0
0
